A 38-year-old male with treatment-resistant schizophrenia has failed adequate trials of risperidone and aripiprazole. The PMHNP plans to initiate clozapine. The FDA discontinued the formal Clozapine REMS program, but ANC monitoring remains the standard of care. Which of the following best describes the recommended monitoring before and during clozapine treatment?